Gapping up
In reaction to strong earnings/guidance: NM +24.6%, NMBL +15.2%, DY +11.3%
M&A news: BIOD +55% (Biodel and Albireo agree to combine through share exchange agreement), CSC +30.2% (HPE announces spinoff of Enterprise Services business with CSC; also reported earnings), HPE +11.9% (announces spinoff of Enterprise Services business with CSC, also reported earnings), MON +2.2% (Bayer (BAYRY) issues statement on MON proposal; remains 'confident' in completing a transaction)
Select EU financial names showing strength: SAN +4.7%, RBS +4.4%, BBVA +4%, DB +3.1%, HSBC +2.8%, CS +2.1%
Select metals stocks trading higher: FCX +2.8%, CLF +2.6%, MT +2.3%, BBL +2.2%, BHP +2.1%, VALE +2%
Select oil/gas related names showing strength: CHK +4.4%, SDLP +3%, WLL +2.5%, BP +1.9%, STO +1.7%, XCO +1.3%
Other news: PTX +24.7% (announces that the USPTO has issued Orange Book patents covering safety information related to dosing patients with Zohydro ER with BeadTek), SRPT +21.9% (announces that the FDA will not complete its review of the Eteplirsen New Drug Application by the PDUFA date), SPEX +14.3% (releases a letter updating shareholders on the co's progress; states it 'is actively exploring viable opportunities outside of the patent monetization space'), GALE +9.2% (in smypathy with other biotech peers showing strength), NVAX +6.4% (FDA has granted Fast Track Designation to its' RSV F-Protein nanoparticle vaccine candidate (RSV F Vaccine) for the protection of older adults), MGI +3.8% (Moneygram & Wal-Mart (WMT) Mexico extend agreement to provide MoneyGram receive services at Wal-Mart locations across the country until 2018), PDLI +3.4% (to make initial $107 mln equity investment in Noden Pharma), NVO +2.7% (receives 16-0 vote from FDA favoring the approval of IDegLira), HPQ +1.9% (in sympathy with HPE), MSFT +0.9% (to cut 1,850 jobs to streamline smartphone hardware business)
Analyst comments: WDC +3% (upgraded to Overweight from Equal Weight at Barclays), ON +2.1% (initiated with a Outperform at Credit Agricole), AMAT +1.7% (upgraded to Buy from Neutral at Citigroup), SHPG +1.6% (initiated with a Buy at Shore Capital)
In reaction to strong earnings/guidance: NM +24.6%, NMBL +15.2%, DY +11.3%
M&A news: BIOD +55% (Biodel and Albireo agree to combine through share exchange agreement), CSC +30.2% (HPE announces spinoff of Enterprise Services business with CSC; also reported earnings), HPE +11.9% (announces spinoff of Enterprise Services business with CSC, also reported earnings), MON +2.2% (Bayer (BAYRY) issues statement on MON proposal; remains 'confident' in completing a transaction)
Select EU financial names showing strength: SAN +4.7%, RBS +4.4%, BBVA +4%, DB +3.1%, HSBC +2.8%, CS +2.1%
Select metals stocks trading higher: FCX +2.8%, CLF +2.6%, MT +2.3%, BBL +2.2%, BHP +2.1%, VALE +2%
Select oil/gas related names showing strength: CHK +4.4%, SDLP +3%, WLL +2.5%, BP +1.9%, STO +1.7%, XCO +1.3%
Other news: PTX +24.7% (announces that the USPTO has issued Orange Book patents covering safety information related to dosing patients with Zohydro ER with BeadTek), SRPT +21.9% (announces that the FDA will not complete its review of the Eteplirsen New Drug Application by the PDUFA date), SPEX +14.3% (releases a letter updating shareholders on the co's progress; states it 'is actively exploring viable opportunities outside of the patent monetization space'), GALE +9.2% (in smypathy with other biotech peers showing strength), NVAX +6.4% (FDA has granted Fast Track Designation to its' RSV F-Protein nanoparticle vaccine candidate (RSV F Vaccine) for the protection of older adults), MGI +3.8% (Moneygram & Wal-Mart (WMT) Mexico extend agreement to provide MoneyGram receive services at Wal-Mart locations across the country until 2018), PDLI +3.4% (to make initial $107 mln equity investment in Noden Pharma), NVO +2.7% (receives 16-0 vote from FDA favoring the approval of IDegLira), HPQ +1.9% (in sympathy with HPE), MSFT +0.9% (to cut 1,850 jobs to streamline smartphone hardware business)
Analyst comments: WDC +3% (upgraded to Overweight from Equal Weight at Barclays), ON +2.1% (initiated with a Outperform at Credit Agricole), AMAT +1.7% (upgraded to Buy from Neutral at Citigroup), SHPG +1.6% (initiated with a Buy at Shore Capital)